Cadila clears USFDA inspection

Cadila Healthcare’s manufacturing facility located in Baddi, has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA), stating that the classification of the facility is in ‘No Action Indicated (NAI)'. The USFDA had conducted inspection at the company’s formulations manufacturing facility at Baddi in Himachal Pradesh from July 15-19, 2019.

Recently, the pharma company announced that its wholly-owned subsidiary, Liva Pharamaceuticals, received the USFDA approval for Haloperidol Decanoate Injection, 50 mg (base)/mL and 100 mg (base)/mL, single-dose vials, 250 mg (base)/5 mL (50 mg (base)/mL) and 500 mg (base)/5 mL (100 mg (base)/mL), multiple-dose vials (US RLD - Haldol Decanoate Injection, 50 mg (base)/mL and 100 mg (base)/mL), used for the treatment of schizophrenia and also to control tics and vocal utterances of Tourette syndrome.

Headquartered in Ahmedabad, Cadila Healthcare is a pharmaceutical company that manufactures generic drugs. The company’s product portfolio consists of a wide range of healthcare products. Being a global healthcare service provider, the company has been able to maintain a significant presence in foreign markets as well.

On Friday, the stock of the company closed at Rs. 255.30, up by 1.59 per cent or Rs. 4 per share. The 52-week high is Rs. 375 and 52-week low is Rs. 206.45 on BSE.